<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958243</url>
  </required_header>
  <id_info>
    <org_study_id>CSLCT-CAL-09-62</org_study_id>
    <nct_id>NCT00958243</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and safety profile of CSL425
      (CSL's 2009 H1N1 influenza vaccine) in a healthy pediatric population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion Rate 21 Days After First Study Vaccination</measure>
    <time_frame>21 days after the first study vaccination</time_frame>
    <description>Seroconversion rate: the percentage of participants achieving seroconversion in HI antibody titer. Seroconversion is defined as participants with a pre-vaccination titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a pre-vaccination HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Rate 21 Days After Second Study Vaccination</measure>
    <time_frame>21 days after the second study vaccination</time_frame>
    <description>Seroconversion rate: the percentage of participants achieving seroconversion in HI antibody titer. Seroconversion is defined as participants with a pre-vaccination titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a pre-vaccination HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After First Study Vaccination</measure>
    <time_frame>21 days after the first study vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After Second Study Vaccination</measure>
    <time_frame>21 days after the second study vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Solicited Adverse Events (AEs) After the First or Second Study Vaccination, Cohort A</measure>
    <time_frame>During the 7 days after each study vaccination</time_frame>
    <description>Grade 3 solicited AE definitions: Prevented normal daily activities or required medical intervention for systemic AEs; Cried when limb was moved/spontaneously painful (aged &lt; 3 years) for injection site pain; Size &gt; 30 mm for injection site redness and injection site induration/swelling; Oral temperature &gt; 104.0°F (40.0°C) or axillary temperature &gt; 103.1°F (39.5°C) for fevers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited Adverse Events After the First and Second Study Vaccination, Cohort A</measure>
    <time_frame>During the 7 days after each study vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Solicited Adverse Events After the First or Second Study Vaccination, Cohort B</measure>
    <time_frame>During the 7 days after each study vaccination</time_frame>
    <description>Grade 3 solicited AE definitions: Prevented normal daily activities or required medical intervention for systemic AEs; Prevented normal daily activities (aged &gt;= 3 years)for injection site pain; Size &gt; 30 mm for injection site redness and injection site induration/swelling; Oral temperature &gt; 104.0°F (40.0°C) or axillary temperature &gt; 103.1°F (39.5°C) for fevers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited Adverse Events After the First and Second Study Vaccination, Cohort B</measure>
    <time_frame>During the 7 days after each study vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Unsolicited Adverse Events (UAE) After the First or Second Vaccination</measure>
    <time_frame>During the 21 days after each vaccination</time_frame>
    <description>UAE grading:
Grade 1: Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2: Enough discomfort to cause some interference with daily activities. Grade 3: Symptoms that prevented normal, everyday activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and New Onset of Chronic Illness (NOCIs)</measure>
    <time_frame>Up to 180 days after the last vaccination</time_frame>
    <description>A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (e.g., diabetes, asthma).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">473</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL425 (7.5 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 mcg of hemagglutinin antigen per dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL425 (15 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mcg of hemagglutinin antigen per dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL's 2009 H1N1 Influenza Vaccine (CSL425)</intervention_name>
    <description>0.5 mL intramuscular injection on Day 0 and Day 21</description>
    <arm_group_label>CSL425 (15 mcg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL's 2009 H1N1 Influenza Vaccine (CSL425)</intervention_name>
    <description>0.25 mL intramuscular injection on Day 0 and Day 21</description>
    <arm_group_label>CSL425 (7.5 mcg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged &gt;= 6 months to &lt; 9 years at the time of the first study
             vaccination.

          -  For children &lt; 3 years of age at the time of first vaccination, born at or after 36
             weeks gestation.

        Exclusion Criteria:

          -  Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to
             eggs, chicken protein, neomycin, polymyxin, or any components of the Study Vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Director Vaccines</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austintown</city>
        <state>Ohio</state>
        <zip>44515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Latrobe</city>
        <state>Pennsylvania</state>
        <zip>15650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <results_first_submitted>July 13, 2011</results_first_submitted>
  <results_first_submitted_qc>July 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2011</results_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Cohort A</title>
          <description>Placebo, Aged 6 months to less than 3 years</description>
        </group>
        <group group_id="P2">
          <title>CSL425 (7.5 mcg) Cohort A</title>
          <description>7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
        </group>
        <group group_id="P3">
          <title>CSL425 (15 mcg) Cohort A</title>
          <description>15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
        </group>
        <group group_id="P4">
          <title>Placebo Cohort B</title>
          <description>Placebo, Aged 3 years to less than 9 years</description>
        </group>
        <group group_id="P5">
          <title>CSL425 (7.5 mcg) Cohort B</title>
          <description>7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
        </group>
        <group group_id="P6">
          <title>CSL425 (15 mcg) Cohort B</title>
          <description>15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="105"/>
                <participants group_id="P3" count="96"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="109"/>
                <participants group_id="P6" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="100"/>
                <participants group_id="P6" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Cohort A</title>
          <description>Placebo, Aged 6 months to less than 3 years</description>
        </group>
        <group group_id="B2">
          <title>CSL425 (7.5 mcg) Cohort A</title>
          <description>7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
        </group>
        <group group_id="B3">
          <title>CSL425 (15 mcg) Cohort A</title>
          <description>15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
        </group>
        <group group_id="B4">
          <title>Placebo Cohort B</title>
          <description>Placebo, Aged 3 years to less than 9 years</description>
        </group>
        <group group_id="B5">
          <title>CSL425 (7.5 mcg) Cohort B</title>
          <description>7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
        </group>
        <group group_id="B6">
          <title>CSL425 (15 mcg) Cohort B</title>
          <description>15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="105"/>
            <count group_id="B3" value="96"/>
            <count group_id="B4" value="28"/>
            <count group_id="B5" value="109"/>
            <count group_id="B6" value="109"/>
            <count group_id="B7" value="473"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="109"/>
                    <measurement group_id="B6" value="109"/>
                    <measurement group_id="B7" value="473"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.87" spread="0.77"/>
                    <measurement group_id="B2" value="1.73" spread="0.72"/>
                    <measurement group_id="B3" value="1.85" spread="0.66"/>
                    <measurement group_id="B4" value="5.90" spread="1.71"/>
                    <measurement group_id="B5" value="5.94" spread="1.71"/>
                    <measurement group_id="B6" value="5.91" spread="1.70"/>
                    <measurement group_id="B7" value="3.93" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="50"/>
                    <measurement group_id="B7" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="56"/>
                    <measurement group_id="B6" value="59"/>
                    <measurement group_id="B7" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="109"/>
                    <measurement group_id="B6" value="109"/>
                    <measurement group_id="B7" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Rate 21 Days After First Study Vaccination</title>
        <description>Seroconversion rate: the percentage of participants achieving seroconversion in HI antibody titer. Seroconversion is defined as participants with a pre-vaccination titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a pre-vaccination HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.</description>
        <time_frame>21 days after the first study vaccination</time_frame>
        <population>The Evaluable Population (for the first vaccination) comprised all randomized participants who received the first study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (e.g., the use of a prohibited medication or a laboratory confirmed infection with 2009 H1N1 between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort A</title>
            <description>Placebo, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg) Cohort A</title>
            <description>7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O4">
            <title>Placebo Cohort B</title>
            <description>Placebo, Aged 3 years to less than 9 years</description>
          </group>
          <group group_id="O5">
            <title>CSL425 (7.5 mcg) Cohort B</title>
            <description>7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
          </group>
          <group group_id="O6">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate 21 Days After First Study Vaccination</title>
          <description>Seroconversion rate: the percentage of participants achieving seroconversion in HI antibody titer. Seroconversion is defined as participants with a pre-vaccination titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a pre-vaccination HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.</description>
          <population>The Evaluable Population (for the first vaccination) comprised all randomized participants who received the first study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (e.g., the use of a prohibited medication or a laboratory confirmed infection with 2009 H1N1 between Visit 1 and Visit 3).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="104"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="0.1" upper_limit="20.4"/>
                    <measurement group_id="O2" value="88.2" lower_limit="80.4" upper_limit="93.8"/>
                    <measurement group_id="O3" value="83.1" lower_limit="73.7" upper_limit="90.2"/>
                    <measurement group_id="O4" value="3.7" lower_limit="0.1" upper_limit="19.0"/>
                    <measurement group_id="O5" value="84.6" lower_limit="76.2" upper_limit="90.9"/>
                    <measurement group_id="O6" value="88.2" lower_limit="80.4" upper_limit="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Rate 21 Days After Second Study Vaccination</title>
        <description>Seroconversion rate: the percentage of participants achieving seroconversion in HI antibody titer. Seroconversion is defined as participants with a pre-vaccination titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a pre-vaccination HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.</description>
        <time_frame>21 days after the second study vaccination</time_frame>
        <population>The Evaluable Population (for the second vaccination) comprised all randomized participants who received the second study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (e.g., the use of a prohibited medication or a laboratory confirmed infection with 2009 H1N1 between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort A</title>
            <description>Placebo, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg) Cohort A</title>
            <description>7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O4">
            <title>Placebo Cohort B</title>
            <description>Placebo, Aged 3 years to less than 9 years</description>
          </group>
          <group group_id="O5">
            <title>CSL425 (7.5 mcg) Cohort B</title>
            <description>7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
          </group>
          <group group_id="O6">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate 21 Days After Second Study Vaccination</title>
          <description>Seroconversion rate: the percentage of participants achieving seroconversion in HI antibody titer. Seroconversion is defined as participants with a pre-vaccination titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a pre-vaccination HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.</description>
          <population>The Evaluable Population (for the second vaccination) comprised all randomized participants who received the second study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (e.g., the use of a prohibited medication or a laboratory confirmed infection with 2009 H1N1 between Visit 1 and Visit 3).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="98"/>
                <count group_id="O6" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="11.3" upper_limit="52.2"/>
                    <measurement group_id="O2" value="98.9" lower_limit="94.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="15.4" lower_limit="4.4" upper_limit="34.9"/>
                    <measurement group_id="O5" value="98.0" lower_limit="92.8" upper_limit="99.8"/>
                    <measurement group_id="O6" value="99.0" lower_limit="94.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Solicited Adverse Events (AEs) After the First or Second Study Vaccination, Cohort A</title>
        <description>Grade 3 solicited AE definitions: Prevented normal daily activities or required medical intervention for systemic AEs; Cried when limb was moved/spontaneously painful (aged &lt; 3 years) for injection site pain; Size &gt; 30 mm for injection site redness and injection site induration/swelling; Oral temperature &gt; 104.0°F (40.0°C) or axillary temperature &gt; 103.1°F (39.5°C) for fevers.</description>
        <time_frame>During the 7 days after each study vaccination</time_frame>
        <population>Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort A</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg) Cohort A</title>
            <description>7.5 mcg of hemagglutinin antigen per dose</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>15 mcg of hemagglutinin antigen per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Solicited Adverse Events (AEs) After the First or Second Study Vaccination, Cohort A</title>
          <description>Grade 3 solicited AE definitions: Prevented normal daily activities or required medical intervention for systemic AEs; Cried when limb was moved/spontaneously painful (aged &lt; 3 years) for injection site pain; Size &gt; 30 mm for injection site redness and injection site induration/swelling; Oral temperature &gt; 104.0°F (40.0°C) or axillary temperature &gt; 103.1°F (39.5°C) for fevers.</description>
          <population>Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling / induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea / vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea / vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited Adverse Events After the First and Second Study Vaccination, Cohort A</title>
        <time_frame>During the 7 days after each study vaccination</time_frame>
        <population>Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.In Cohort A, Safety Population after the first vaccination are placebo group 26, 7.5 mcg group 105 and 15 mcg group 96; and 25, 101 and 91 respectively after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort A</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg) Cohort A</title>
            <description>7.5 mcg of hemagglutinin antigen per dose</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>15 mcg of hemagglutinin antigen per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Adverse Events After the First and Second Study Vaccination, Cohort A</title>
          <population>Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.In Cohort A, Safety Population after the first vaccination are placebo group 26, 7.5 mcg group 105 and 15 mcg group 96; and 25, 101 and 91 respectively after the second vaccination.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.000"/>
                    <measurement group_id="O2" value="1.52" spread="0.677"/>
                    <measurement group_id="O3" value="1.91" spread="1.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.577"/>
                    <measurement group_id="O2" value="2.20" spread="1.323"/>
                    <measurement group_id="O3" value="2.56" spread="1.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.707"/>
                    <measurement group_id="O2" value="1.63" spread="0.957"/>
                    <measurement group_id="O3" value="2.00" spread="1.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="3.215"/>
                    <measurement group_id="O2" value="1.32" spread="0.557"/>
                    <measurement group_id="O3" value="1.29" spread="0.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea / vomiting after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.000"/>
                    <measurement group_id="O2" value="1.43" spread="0.535"/>
                    <measurement group_id="O3" value="1.11" spread="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.707"/>
                    <measurement group_id="O2" value="2.38" spread="1.996"/>
                    <measurement group_id="O3" value="3.95" spread="4.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00">Only one participant reported this AE after the first study vaccination in this group.</measurement>
                    <measurement group_id="O2" value="3.13" spread="2.500"/>
                    <measurement group_id="O3" value="2.07" spread="1.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="7.810"/>
                    <measurement group_id="O2" value="2.08" spread="1.412"/>
                    <measurement group_id="O3" value="1.97" spread="1.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.787"/>
                    <measurement group_id="O2" value="1.57" spread="0.676"/>
                    <measurement group_id="O3" value="1.23" spread="0.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="2.608"/>
                    <measurement group_id="O2" value="2.00" spread="1.240"/>
                    <measurement group_id="O3" value="1.63" spread="0.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00">Only one participant reported this AE after the second study vaccination in this group.</measurement>
                    <measurement group_id="O2" value="3.00" spread="2.098"/>
                    <measurement group_id="O3" value="2.50" spread="0.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.894"/>
                    <measurement group_id="O2" value="1.40" spread="0.894"/>
                    <measurement group_id="O3" value="2.19" spread="2.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea / vomiting after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants reported this AE after the second study vaccination in this group.</measurement>
                    <measurement group_id="O2" value="1.27" spread="0.647"/>
                    <measurement group_id="O3" value="1.50" spread="0.837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="9.899"/>
                    <measurement group_id="O2" value="1.92" spread="1.248"/>
                    <measurement group_id="O3" value="4.33" spread="6.754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.707"/>
                    <measurement group_id="O2" value="1.75" spread="1.183"/>
                    <measurement group_id="O3" value="3.60" spread="5.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.577"/>
                    <measurement group_id="O2" value="1.81" spread="1.001"/>
                    <measurement group_id="O3" value="2.86" spread="4.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Solicited Adverse Events After the First or Second Study Vaccination, Cohort B</title>
        <description>Grade 3 solicited AE definitions: Prevented normal daily activities or required medical intervention for systemic AEs; Prevented normal daily activities (aged &gt;= 3 years)for injection site pain; Size &gt; 30 mm for injection site redness and injection site induration/swelling; Oral temperature &gt; 104.0°F (40.0°C) or axillary temperature &gt; 103.1°F (39.5°C) for fevers.</description>
        <time_frame>During the 7 days after each study vaccination</time_frame>
        <population>Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort B</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg) Cohort B</title>
            <description>7.5 mcg of hemagglutinin antigen per dose</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>15 mcg of hemagglutinin antigen per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Solicited Adverse Events After the First or Second Study Vaccination, Cohort B</title>
          <description>Grade 3 solicited AE definitions: Prevented normal daily activities or required medical intervention for systemic AEs; Prevented normal daily activities (aged &gt;= 3 years)for injection site pain; Size &gt; 30 mm for injection site redness and injection site induration/swelling; Oral temperature &gt; 104.0°F (40.0°C) or axillary temperature &gt; 103.1°F (39.5°C) for fevers.</description>
          <population>Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling / induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea / vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea / vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After First Study Vaccination</title>
        <time_frame>21 days after the first study vaccination</time_frame>
        <population>The Evaluable Population (for the first vaccination) comprised all randomized participants who received the first study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (e.g., the use of a prohibited medication or a laboratory confirmed infection with 2009 H1N1 between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort A</title>
            <description>Placebo, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg) Cohort A</title>
            <description>7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O4">
            <title>Placebo Cohort B</title>
            <description>Placebo, Aged 3 years to less than 9 years</description>
          </group>
          <group group_id="O5">
            <title>CSL425 (7.5 mcg) Cohort B</title>
            <description>7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
          </group>
          <group group_id="O6">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After First Study Vaccination</title>
          <population>The Evaluable Population (for the first vaccination) comprised all randomized participants who received the first study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (e.g., the use of a prohibited medication or a laboratory confirmed infection with 2009 H1N1 between Visit 1 and Visit 3).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="104"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="1.0" upper_limit="26.0"/>
                    <measurement group_id="O2" value="90.2" lower_limit="82.7" upper_limit="95.2"/>
                    <measurement group_id="O3" value="84.3" lower_limit="75.0" upper_limit="91.1"/>
                    <measurement group_id="O4" value="25.9" lower_limit="11.1" upper_limit="46.3"/>
                    <measurement group_id="O5" value="84.6" lower_limit="76.2" upper_limit="90.9"/>
                    <measurement group_id="O6" value="89.2" lower_limit="81.5" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After Second Study Vaccination</title>
        <time_frame>21 days after the second study vaccination</time_frame>
        <population>The Evaluable Population (for the second vaccination) comprised all randomized participants who received the second study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (e.g., the use of a prohibited medication or a laboratory confirmed infection with 2009 H1N1 between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort A</title>
            <description>Placebo, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg) Cohort A</title>
            <description>7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O4">
            <title>Placebo Cohort B</title>
            <description>Placebo, Aged 3 years to less than 9 years</description>
          </group>
          <group group_id="O5">
            <title>CSL425 (7.5 mcg) Cohort B</title>
            <description>7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
          </group>
          <group group_id="O6">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After Second Study Vaccination</title>
          <population>The Evaluable Population (for the second vaccination) comprised all randomized participants who received the second study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (e.g., the use of a prohibited medication or a laboratory confirmed infection with 2009 H1N1 between Visit 1 and Visit 3).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="98"/>
                <count group_id="O6" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="11.3" upper_limit="52.2"/>
                    <measurement group_id="O2" value="98.9" lower_limit="94.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="34.6" lower_limit="17.2" upper_limit="55.7"/>
                    <measurement group_id="O5" value="98.0" lower_limit="92.8" upper_limit="99.8"/>
                    <measurement group_id="O6" value="100.0" lower_limit="96.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited Adverse Events After the First and Second Study Vaccination, Cohort B</title>
        <time_frame>During the 7 days after each study vaccination</time_frame>
        <population>Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data. In Cohort B, Safety Population after the first vaccination are placebo group 28, 7.5 mcg group 107 and 15 mcg group 109; and 27, 105 and 103 respectively after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort B</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg) Cohort B</title>
            <description>7.5 mcg of hemagglutinin antigen per dose</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>15 mcg of hemagglutinin antigen per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Adverse Events After the First and Second Study Vaccination, Cohort B</title>
          <population>Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data. In Cohort B, Safety Population after the first vaccination are placebo group 28, 7.5 mcg group 107 and 15 mcg group 109; and 27, 105 and 103 respectively after the second vaccination.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.516"/>
                    <measurement group_id="O2" value="1.63" spread="1.066"/>
                    <measurement group_id="O3" value="1.46" spread="0.691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="1.254"/>
                    <measurement group_id="O2" value="2.17" spread="1.339"/>
                    <measurement group_id="O3" value="2.24" spread="1.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.732"/>
                    <measurement group_id="O2" value="1.80" spread="0.632"/>
                    <measurement group_id="O3" value="1.79" spread="0.975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="0.447"/>
                    <measurement group_id="O2" value="1.12" spread="0.332"/>
                    <measurement group_id="O3" value="1.56" spread="0.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea / vomiting after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.000"/>
                    <measurement group_id="O2" value="1.25" spread="0.500"/>
                    <measurement group_id="O3" value="1.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.354"/>
                    <measurement group_id="O2" value="1.00" spread="0.000"/>
                    <measurement group_id="O3" value="1.22" spread="0.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.744"/>
                    <measurement group_id="O2" value="1.47" spread="0.964"/>
                    <measurement group_id="O3" value="1.60" spread="0.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.548"/>
                    <measurement group_id="O2" value="1.42" spread="0.669"/>
                    <measurement group_id="O3" value="1.56" spread="0.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache after first vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.894"/>
                    <measurement group_id="O2" value="1.15" spread="0.376"/>
                    <measurement group_id="O3" value="1.25" spread="0.645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.500"/>
                    <measurement group_id="O2" value="1.56" spread="0.856"/>
                    <measurement group_id="O3" value="1.33" spread="0.555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.000"/>
                    <measurement group_id="O2" value="1.67" spread="0.516"/>
                    <measurement group_id="O3" value="1.60" spread="0.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00">Only one participant reported this AE after the second study vaccination in this group.</measurement>
                    <measurement group_id="O2" value="1.17" spread="0.408"/>
                    <measurement group_id="O3" value="1.63" spread="0.744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00">Only one participant reported this AE after the second study vaccination in this group.</measurement>
                    <measurement group_id="O2" value="1.40" spread="0.548"/>
                    <measurement group_id="O3" value="1.57" spread="1.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea / vomiting after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00">Only one participant reported this AE after the second study vaccination in this group.</measurement>
                    <measurement group_id="O2" value="1.25" spread="0.500"/>
                    <measurement group_id="O3" value="1.17" spread="0.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1">Only one participant reported this AE after the second study vaccination in this group.</measurement>
                    <measurement group_id="O2" value="1.00" spread="0.000"/>
                    <measurement group_id="O3" value="1.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.707"/>
                    <measurement group_id="O2" value="1.75" spread="0.754"/>
                    <measurement group_id="O3" value="1.83" spread="1.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00">Only one participant reported this AE after the second study vaccination in this group.</measurement>
                    <measurement group_id="O2" value="1.38" spread="0.518"/>
                    <measurement group_id="O3" value="1.42" spread="0.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.707"/>
                    <measurement group_id="O2" value="1.38" spread="0.518"/>
                    <measurement group_id="O3" value="1.29" spread="0.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Unsolicited Adverse Events (UAE) After the First or Second Vaccination</title>
        <description>UAE grading:
Grade 1: Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2: Enough discomfort to cause some interference with daily activities. Grade 3: Symptoms that prevented normal, everyday activities.</description>
        <time_frame>During the 21 days after each vaccination</time_frame>
        <population>Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort A</title>
            <description>Placebo, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg) Cohort A</title>
            <description>7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O4">
            <title>Placebo Cohort B</title>
            <description>Placebo, Aged 3 years to less than 9 years</description>
          </group>
          <group group_id="O5">
            <title>CSL425 (7.5 mcg) Cohort B</title>
            <description>7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
          </group>
          <group group_id="O6">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Unsolicited Adverse Events (UAE) After the First or Second Vaccination</title>
          <description>UAE grading:
Grade 1: Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2: Enough discomfort to cause some interference with daily activities. Grade 3: Symptoms that prevented normal, everyday activities.</description>
          <population>Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="107"/>
                <count group_id="O6" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Proportion of participants with at least one UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of participants reported Grade 1 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of participants reported Grade 2 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of participants reported Grade 3 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and New Onset of Chronic Illness (NOCIs)</title>
        <description>A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (e.g., diabetes, asthma).</description>
        <time_frame>Up to 180 days after the last vaccination</time_frame>
        <population>Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Cohort A</title>
            <description>Placebo, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg) Cohort A</title>
            <description>7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O4">
            <title>Placebo Cohort B</title>
            <description>Placebo, Aged 3 years to less than 9 years</description>
          </group>
          <group group_id="O5">
            <title>CSL425 (7.5 mcg) Cohort B</title>
            <description>7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
          </group>
          <group group_id="O6">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and New Onset of Chronic Illness (NOCIs)</title>
          <description>A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (e.g., diabetes, asthma).</description>
          <population>Safety Population comprised all randomized participants who received at least one dose of study vaccine and had provided follow-up safety data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="107"/>
                <count group_id="O6" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Proportion of participants with at least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of participants with related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of participants with at least one AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of participants with related AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of participants with at least one NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of participants with related NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>180 days after the last study vaccination for SAEs. 21 days after each study vaccination for unsolicited adverse events.</time_frame>
      <desc>Other adverse events presented are unsolicited adverse events 21 days after either study vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Cohort A</title>
          <description>Placebo, Aged 6 months to less than 3 years</description>
        </group>
        <group group_id="E2">
          <title>CSL425 (7.5 mcg) Cohort A</title>
          <description>7.5 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
        </group>
        <group group_id="E3">
          <title>CSL425 (15 mcg) Cohort A</title>
          <description>15 mcg of hemagglutinin antigen per dose, Aged 6 months to less than 3 years</description>
        </group>
        <group group_id="E4">
          <title>Placebo Cohort B</title>
          <description>Placebo, Aged 3 years to less than 9 years</description>
        </group>
        <group group_id="E5">
          <title>CSL425 (7.5 mcg) Cohort B</title>
          <description>7.5 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
        </group>
        <group group_id="E6">
          <title>CSL425 (15 mcg) Cohort B</title>
          <description>15 mcg of hemagglutinin antigen per dose, Aged 3 years to less than 9 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="107"/>
                <counts group_id="E6" subjects_affected="49" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E5" events="17" subjects_affected="15" subjects_at_risk="107"/>
                <counts group_id="E6" events="11" subjects_affected="10" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="105"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E3" events="21" subjects_affected="17" subjects_at_risk="96"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E5" events="22" subjects_affected="21" subjects_at_risk="107"/>
                <counts group_id="E6" events="17" subjects_affected="15" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Study Disclosure Manager</name_or_title>
      <organization>Seqirus</organization>
      <phone>1-855-358-8966</phone>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

